If A-SAA is a marker of or causal link between obesity and its metabolic and cardiovascular complications, we would predict that circulating A-SAA levels would decrease in response to interventions that decrease obesity or its metabolic complications, e.g., insulin resistance. The gene discussed is SAA1; the disease is obesity due to melanocortin 4 receptor deficiency.